Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 17, 1987 - Issue 1
18
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Pharmacokinetics of xamoterol glucuronidation in the rat in vivo and in liver perfusion

, , &
Pages 85-92 | Received 15 Dec 1985, Published online: 30 Sep 2009
 

Abstract

1. Xamoterol has a phenolic hydroxyl group at which both sulphation and glucuronidation may occur. In the rat in vim it is almost exclusively glucuronidated. In bile the glucuronide conjugate is the only metabolite of xamoterol. In urine equal amounts of the glucuronide conjugate and unchanged xamoterol are present, together with a small amount of the sulphate conjugate (approx. 1% of the dose).

2. The t1/2 of excretion of the glucuronide in bile was the same as the t1/2 for excretion of unchanged xamoterol in urine. The t1/2 for urinary excretion of the glucuronide conjugate was longer than that for its biliary excretion.

3. In the isolated perfused rat liver glucuronidation was also the almost exclusive metabolic pathway. The extraction ratio of xamoterol by the liver was approx. 0.15.

4. Since xamoterol is a very water-soluble compound, and is almost exclusively glucuronidated in the rat, it is an excellent model substrate for investigations on the pharmacokinetics of glucuronidation in the rat in vivo and in isolated perfused organs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.